HAVCR2 and acute myeloid leukemia: We observed that patients with high HAVCR2 expression in BM cells at diagnosis showed significantly improved survival compared with patients with low HAVCR2 expression when analyzing the target-AML cohort (58), comprising 1,630 low and 276 high TIM-3–expressing BM patient samples (Figure 8F).